Background and objective: A single assessment of within-breath variations of respiratory system reactance (Xrs) at 5 Hz (ΔX5) measured by the forced oscillation technique (FOT) has been reported to be useful for the detection of pathophysiological changes in chronic obstructive pulmonary disease (COPD) and asthma. We examined longitudinal changes in respiratory system resistance (Rrs) and Xrs during tidal breathing between stable asthma and COPD patients in order to clarify the features of changes of respiratory system impedance and airflow limitation for these conditions. Methods: Between April 2013 and September 2013, outpatients with a COPD or asthma diagnosis were recruited. We examined forced expiratory volume in 1 s (FEV 1 ) and FOT every 6 months until September 2015. Annual changes were estimated from the linear regression curve slope. Results: We included 57 and 93 subjects with COPD and asthma, respectively. The median follow-up period was 26 months (range: 24-29 months). Within-breath analysis showed that the difference between mean Rrs at 5 Hz and 20 Hz was significantly lower, and ΔX5 more negative, in COPD than in asthma patients. With regard to annual changes, only ΔX5 was significantly different, more negative, in COPD than in asthma patients. Comparing between COPD subjects of Global Initiative Chronic Obstructive Lung Disease (GOLD) stage I/II and those with asthma, there were no significant differences in respiratory system impedance at enrolment, while annual change in ΔX5 was significantly more negative in mild COPD than in asthma patients. Conclusion: ΔX5 may be useful for long-term assessment of airflow limitation in COPD.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airway flow limitation that is not fully reversible. This flow limitation is mainly caused by airway wall remodelling and a loss of alveolar attachment and elastic recoil in small airways. 1 Asthma, on the other hand, is characterized by reversible flow limitation due to airway inflammation resulting in oedema of the airway walls, mucus hypersecretion and the constriction of airway smooth muscle. 2 However, some asthma patients show irreversible airflow limitation due to airway remodelling. [3] [4] [5] Although there are some differences in the pathophysiological changes causing airway flow limitation in patients with COPD or asthma, spirometry cannot always distinguish these differences. 6 The forced oscillation technique (FOT) is a noninvasive method for measuring lung mechanics. 7 The real part of impedance is termed respiratory system resistance (Rrs), whereas the imaginary part of impedance is called respiratory system reactance (Xrs), which reflects the elastic and inertial properties of the respiratory system. 7 Recently, the usefulness of FOT in the evaluation and management of obstructive lung diseases, including asthma and COPD, was described. [8] [9] [10] Previous cross-sectional studies reported that withinbreath variations of Xrs at 5 Hz (ΔX5) were useful for detecting the different pathophysiological changes in the airway between COPD and asthma. 6 Dellacà et al. reported that ΔX5 measured with FOT allowed the detection of expiratory flow limitation (EFL). [11] [12] [13] This
SUMMARY AT A GLANCE
Changes in a single assessment of within-breath variations of respiratory system reactance (Xrs) at 5 Hz (ΔX5) in patients with chronic obstructive pulmonary disease (COPD) are significantly greater than in patients with asthma. ΔX5 may reflect the pathophysiological changes in COPD and can be useful for its long-term assessment.
phenomenon is common in patients with severe COPD, and is a major determinant of dynamic hyperinflation and exercise limitation. EFL is caused by the loss of lung elastic recoil. It is supposed that reactance normally reflects the elastic properties of the respiratory system; however, with flow limitation, oscillatory signals cannot pass through the choke points and reach the alveoli, producing a marked reduction in the apparent compliance and a reduction in reactance. [11] [12] [13] In fact, dynamic airway narrowing during quiet breathing at rest has been visually detected in a patient with severe COPD by high-speed electron beam computed tomography (CT).
14 Based on this pathophysiological theory, we hypothesized that the decrease of ΔX5 reflected the progressive loss of lung elastic recoil in COPD and ΔX5 decreased more significantly in COPD than in asthma patients. To date, comparisons between the long-term changes in the respiratory system in subjects with COPD and asthma have not been drawn. The purpose of this study was to examine the different patterns of longitudinal changes in Rrs and Xrs during tidal breathing between patients with stable asthma and COPD, and to clarify the differences in pathophysiological airway changes between these two obstructive lung diseases.
METHODS
Between April 2013 and September 2013, outpatients with a diagnosis of COPD or asthma who attended Kobe City Medical Center West Hospital (a 358-bed community teaching hospital, Kobe, Japan) were recruited and followed up until September 2015.
All patients with COPD fulfilled the following inclusion criteria which had been used in our previous study 15 : (i) a smoking history of more than 20 packyears; (ii) maximal forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (FVC) ratio (FEV 1 %) of <0.7; (iii) regular management and treatment at our outpatient clinic over 6 months; (iv) no exacerbations requiring systemic corticosteroid and/or antibiotics in the previous 3 months; (v) no other lung diseases or uncontrolled co-morbidities such as severe cardiovascular diseases and malignant disorders; and (vi) sufficient cognitive function to complete the questionnaire. The staging of COPD was assessed in accordance with the Global Initiative Chronic Obstructive Lung Disease (GOLD) 2014 guidelines. We classified GOLD stages I and II as mild COPD, and stages III and IV as severe COPD.
All patients with asthma fulfilled the following inclusion criteria which had been used in our previous study 16 : (i) a history of episodic dyspnoea and wheezing, and the presence of significant airway reversibility; (ii) had been receiving inhaled corticosteroids or a combination of inhaled corticosteroids with other medications including long-acting β2-agonists, leukotriene receptor antagonists or sustained release theophylline for at least 6 months; (iii) no exacerbations requiring systemic corticosteroid in the previous 3 months; (iv) a ≤10-pack-year smoking history; and (v) no other lung diseases or uncontrolled co-morbidities such as severe cardiovascular diseases and malignant disorders.
Measurements of the patients' baseline characteristics (age, sex, body mass index (BMI)), lung function tests (post-bronchodilator FEV 1 ), FOT, blood tests (eosinophils and immunoglobulin E), fractional exhaled nitric oxide (FeNO), COPD assessment 17 and the asthma control test 18 were performed at enrolment. FEV 1 and FOT assessments were performed every 6 months until September 2015. The same equipment and standardized methods were used for all examinations.
Some previous studies have claimed that ΔX5 is significantly greater in COPD than in asthma, and that ΔX5 is useful for detecting the different pathophysiological changes in these two diseases. 6, 8 However, as ΔX5 increases with the severity of COPD, 6 there is the possibility that there is no significant difference in ΔX5 between asthma and mild COPD. Furthermore, other previous studies showed that emphysematous lesions progressed in COPD in longitudinal assessments using CT 19, 20 and predicted that FEV 1 % was significantly lowered in accordance with the severity of emphysema. 21 As emphysema may often be obscured in mild COPD, 22 it might be more difficult, in a clinical setting, to distinguish the pathophysiological changes of asthma from those of mild COPD, as opposed to severe COPD. In our study, we compared respiratory system impedance between asthma and mild COPD.
The study was approved by the Institutional Review Board of the Kobe City Medical Center West Hospital (reference number 14-023 and 14-024) and informed consent was obtained from all patients before enrolment in the study.
Measurements

Lung function tests
After the patients had inhaled bronchodilators (400 μg of salbutamol), spirometry was performed and subdivisions of the lung volume were measured with a Chestac-65V (Chest MI, Inc., Tokyo, Japan). The predicted pulmonary function test values were calculated based on the Japanese Respiratory Society guidelines. 23 In this study, FEV 1 refers to post-bronchodilator FEV 1 .
Forced oscillation technique
After inhaled bronchodilator use (400 μg of salbutamol), respiratory impedance was measured with a commercially available FOT device (MostGraph-01, Chest MI, Inc.). During the measurements, subjects were placed in the seated position, wore a nose clip and breathed at tidal volume through a mouthpiece. In addition, they supported their cheeks to reduce upper airway shunting. A noise signal was applied to the airway, and the respiratory system impedance was automatically calculated using the MostGraph-01 software (version 1.31, Chest MI, Inc.). Recordings were performed for 60 s after steady breathing was confirmed. The mean Rrs at 5 Hz (R5), mean Rrs at 20 Hz (R20), their difference (R5 − R20), Xrs at 5 Hz (X5) and resonant frequency (Fres) were calculated (whole-breath analysis). The differences between the mean Rrs, Xrs and Fres in the expiratory phase and those in the inspiratory phase were also examined (expressed as within-breath or Delta). We excluded measurements of abnormal actions such as coughing and speech. Whole-breath analysis and within-breath analysis were performed automatically by the software. The average levels of at least three acceptable measurements were used (Figs 1-2) . 
Statistical analysis
All statistical analyses were performed using the JMP 9 software (SAS Institute, Cary, NC, USA). Categorical data were summarized as counts, and quantitative data were summarized as the median. Annual changes were estimated from doubling the slope of the linear regression curve, which was calculated with data distributed in intervals of 6 months. Baseline variables and annual changes between these groups were compared using the chisquare test for categorical variables and unpaired t-tests or Mann-Whitney U-tests as appropriate for continuous variables. Statistical significance was defined as P < 0.05.
RESULTS
Sixty subjects with COPD and 97 subjects with asthma were initially included; the final study population comprised 57 and 93 subjects with COPD and asthma, respectively. The reasons of exclusion were as follows: death (one subject), new lung lesions (one subject) and loss to follow-up (one subject) in the COPD group, and death (one subject), house-moving (one subject) and loss to follow-up (two subjects) in the asthma group. The characteristics of the study subjects, and the baseline respiratory system impedance and lung function tests values, are shown in Tables 1  and 2 , respectively. There were no significant differences in whole-breath respiratory system impedance between subjects with COPD and asthma. However, within-breath analysis showed that ΔR5 − R20 was lower and ΔX5 was more negative in subjects with COPD than in those with asthma. The annual changes in respiratory system impedance and FEV 1 are shown in Table 3 . The annual change in ΔX5 was the only parameter that was significantly different between Values are the median (25-75%). *P < 0.05. Δ, Difference between inspiratory and expiratory phases. FEV 1 , forced expiratory volume in 1 s; Fres, resonant frequency; R5 and R20, respiratory system resistance at 5 and 20 Hz, respectively; X5, respiratory system reactance at 5 Hz.
groups; it was more negative in subjects with COPD than in those with asthma.
We then compared subjects with mild (n = 30) and severe COPD (n = 27) (Tables S1-S4, Supplementary Information). At enrolment, there were no significant differences in whole-breath Rrs, while within-breath ΔR5 (Table S3 , Supplementary Information). In the longitudinal assessment, whole-breath Rrs and Fres increased, and X5 decreased annually. On the other hand, in the within-breath analysis, although Rrs and Xrs decreased in mild COPD, these parameters increased in severe COPD annually (Table S4, Supplementary  Information) . Finally, we compared respiratory system impedance between mild COPD and asthma. Subjects with asthma were divided into two groups, those with an FEV 1 % <70% (n = 34) and those with an FEV 1 ≥70% (n = 59), and these two groups were compared with the mild COPD group (Table 4) . There were no significant differences in respiratory system impedance at enrolment (data not shown), while the annual change in withinbreath X5 was significantly more negative in mild COPD ( 
DISCUSSION
This prospective observational study aimed to examine the different patterns of longitudinal changes in respiratory system impedance during tidal breathing between stable asthma and COPD patients, and to clarify the differences in pathophysiological airway changes between the two diseases. To the best of our knowledge, this study is the first to demonstrate that ΔX5 decreases annually in COPD and that there is a significant difference in the annual changes of ΔX5 between subjects with COPD and those with asthma. Furthermore, there was a significant difference in ΔX5 between mild COPD and asthma, not in the cross-sectional assessment, but in the annual change. In mild COPD, the loss of lung elastic coil and EFL was not severe, and there was no difference of single assessments of ΔX5 between mild COPD and asthma patients. However, with disease progression, lung elastic coil and EFL deteriorated, which might reflect on decrease of ΔX5 in mild COPD. Longitudinal changes in ΔX5 may be useful for long-term assessments of COPD.
In our study, we reported the longitudinal changes of lung function and respiratory system impedance at intervals of 6 months. ΔX5 decreased in mild COPD, but increased in severe COPD, suggesting that in mild COPD, the progressive loss of lung elastic coil could be more significant than in severe COPD. The influence of deterioration of EFL on ΔX5 was significant in mild COPD. However, the reason for this result is unclear, because not only emphysema but also airway lesions influence Xrs. More studies to clarify the meaning of the different patterns of ΔX5 changes between mild and severe COPD are needed. Although Kanda et al. reported that ΔX5 decreases with the severity of COPD, 6 which was also shown in our study, our results might suggest that the longitudinal change of ΔX5 is more meaningful than a single measurement, and the high value of ΔX5 could be a sign of severe COPD.
In our study, we compared respiratory system impedance between asthma and mild COPD. Although there was no significant difference in ΔX5 at enrolment between asthma (whole, FEV 1 % <70% and FEV 1 % ≥70%) and mild COPD, the annual change in ΔX5 was significantly greater in mild COPD subjects. Although there were significant differences in the degree of airflow limitation between COPD and asthma patients at enrolment, this result suggested that disease-specific factor such as EFL had more significant impact on the change of ΔX5 than the baseline airflow limitation. This emphasized the importance of assessing changes in respiratory system impedance, especially ΔX5, in obstructive lung diseases. In this study, we excluded asthma patients with a >10-pack-year smoking history to clarify the different pathophysiological changes between COPD and asthma. However, there are smoking asthma patients who may have COPD or an overlap of asthma and COPD. In these patients, our findings suggest that the deterioration of ΔX5 reflect the changes of small airway lesions and the involvement of COPD. To clarify this, more studies are needed.
The present study had a few limitations. First, it was a single-centre investigation; therefore, some selection bias might have affected the findings. Second, the study was based on a small number of patients, and in particular, the number of subjects of GOLD stage IV was small. Therefore, a larger study population is required to validate the results. Third, changing and/or additional treatment during the observation period may have influenced the results. Fourth, the COPD patients were older than the asthmatic patients. Although age has a slight influence on respiratory system impedance, we do not believe this issue would have a significant impact on our results. Fifth, because this study was based on a daily clinical practice, some patients finished this study at the 25th-27th month.
In conclusion, our study indicates that the annual change of ΔX5 is greater in COPD than in asthma patients. ΔX5 may reflect the pathophysiological changes in COPD and may be useful for the long-term assessment and management of COPD. Further studies are needed to clarify the significance of changes of ΔX5 in COPD.
Table S1
Changes of respiratory system impedance and FEV 1 of severe COPD (GOLD stage III/IV). Table S2 Changes of respiratory system impedance and FEV 1 of severe COPD (GOLD stage I/II). Table S3 Respiratory system impedance and FEV 1 of mild COPD (GOLD stage I/II) and severe COPD (GOLD stage III/IV) at enrolment. Table S4 Annual changes of respiratory system impedance and FEV 1 of mild COPD (GOLD stage I/II) and severe COPD (GOLD stage III/IV).
